Advertisement

Topics

Search Results for "Sjogren A Belimumab"

03:16 EDT 26th March 2017 | BioPortfolio

Matching Channels

None

Matching News

Real-world belimumab reduces disease activity in patients with lupus

Belimumab reduced disease activity and corticosteroid use after 6 months, according to real-world results published in Rheumatology and Therapy.“The OBSErve Germany study provides the first insight ...

A chance diagnosis of Sjogren’s syndrome heralded the start of Stephen McPhail’s long road to recovery

  All footballers feel lucky to be living the dream but Stephen McPhail appreciates his place on the pitch more than most.Not only has he successfully defeated cancer in the form of non-Hodgkin...

BRIEF-GSK submits regulatory application in Japan for belimumab

* Submits regulatory application in Japan for belimumab in systemic lupus erythematosus Further company coverage: (Bengaluru Newsroom)

GSK’s Benlysta® (belimumab) shows sustained benefits in patients with SLE

GSK submits regulatory application in Japan for belimumab in systemic lupus erythematosus

GSK announces positive results in fourth consecutive pivotal trial of Benlysta® (belimumab) in SLE

Belimumab for Lupus: Helpful in the Real World (CME/CE)

(MedPage Today) -- More than half had improvement of 50% or more at 6 months

Human medicines European public assessment report (EPAR): Benlysta, belimumab, Revision: 15, Authorised

Matching PubMed Articles

New onset of lupus nephritis in two patients with SLE shortly after initiation of treatment with belimumab.

Belimumab is currently approved for the treatment of patients with active SLE despite standard treatment. However, it has not been formally tested for patients with lupus nephritis because such patien...

Efficacy and safety of subcutaneous belimumab in systemic lupus erythematosus: A randomized, double-blind, placebo-controlled, 52-week study.

Objective To assess the efficacy and safety of subcutaneous (SC) belimumab in patients with systemic lupus erythematosus (SLE). Methods Patients with moderate-to-severe SLE (SELENA-SLEDAI ≥8) were r...

Efficacy of belimumab on renal outcomes in patients with systemic lupus erythematosus: A systematic review.

Both BLISS-52 and BLISS-76 international phase III trials in Systemic Lupus Erythematosus (SLE) met their primary outcomes; however, they were not designed to assess the efficacy of belimumab for the ...

Evaluation of a novel autoinjector for subcutaneous self-administration of belimumab in systemic lupus erythematosus
.

To study self-administration and pharmacokinetics (PK) of subcutaneous (SC) belimumab in patients with systemic lupus erythematosus (SLE).

Belimumab for the treatment of recalcitrant cutaneous lupus.

Background Belimumab is a monoclonal antibody that reduces B lymphocyte survival by blocking the binding of soluble human B lymphocyte stimulator (BLyS) to its B cell receptors. The utility of belimum...

Search Whole site using Google

Loading
Quick Search
Advertisement
 
Advertisement Advertisement